|
“Good interaction between delegates.”
Magnus Korsgren, Associate Professor Research Physician, Astrazeneca, Speaker, SMi’s Asthma & COPD Conference 2009
COPD is the fourth biggest killer in Europe, with mortality continuing to rise at a time when the mortality rates associated with cardiovascular diseases are declining. Affecting up to 10% of adults COPD causes around 300,000 deaths in Europe every year. With a strong link visible between smoking and development of the disease, smoking cessation is currently the only successful method to slow the worsening of the disease. The drugs to manage the symptomes of COPD are often designed for use in asthma, meaning there are very few drugs developed for COPD alone.
SMi's 2009 COPD: Novel Therapeutics and Management Strategies conference aims to address the imbalance in research between Asthma & COPD, and place the spotlight firmly on COPD alone. This conference will bring together industry experts to discuss the latest research developments in drug discovery and development, alongside the technological advancements in drug formulation and inhalation delivery methods.
Why should you attend this event?
This conference provides a much needed opportunity to focus on the challenges faced in the development of drugs for those suffering from COPD.
Key Benefits of Attending:
- HEAR from leading researchers in the COPD field
- DISCUSS novel therapeutics and the hopes for the future
- LEARN about the important differences between Asthma & COPD, causing the need for unique therapies
- DISCOVER the latest developments in inhalation technology for the treatment of COPD
Hear keynote addresses from:
Professor Robert Stockley, Professor of Medicine, University of Birmingham
Frank Thielmann, Fellow, PDU Inhalation, Novartis
Our expert speaker line-up also includes:
Ian Anderson, Vice President of Research, Respiratory, Inflammation and Autoimmunity, MedImmune
Matthew Catley, Senior Scientist, UCB Celltech
Tim Higenbottam, Head of Corporate Clinical Development, Chiesi Farmaceutica
Philip Monk, Head of Development, Synairgen
Fadi Eskandar, Inhalation Development Unit, Novartis
Professor Claus Vogelmeier, Professor and Chairman at the Department for Pulmonary Medicine, Philipps University of Marburg
Liz Hardaker, Novartis
Professor Norbert Krug, Medical Director, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM)
Anders Fuglsang, Clinical & Regulatory Strategy Manager, Aeropharm
Christian Hesslinger, Associate Director and Head of In-Vitro Biology, Nycomed
Who should attend?
Delegates at our Asthma & COPD conference this year included:
- AstraZeneca, Director of Discovery Medicine
- Imperial College, Professor of Thoracic Medicine
- Kings College London, Professor
- Synairgen, Head of Development
- Astrazeneca R & D Lund, Associate Professor Research Physician
- Boehringer Ingelheim, Vice President
- Fibrex Medical Inc, VP, Research
- Boehringer Ingelheim, Research & Development
- GlaxoSmithKline, European Regulatory Affairs
- Boehringer Ingelheim, Senior Scientific Adviser
- Laboratorios Almirall, New Products Manager
- Napp Pharmaceuticals, Brand Manager
- Nycomed, Senior Scientist
- Pfizer, Director, Senior Clinical Scientist
- Sanofi-Aventis, Head of Marketing
- Syntaxin, Head of DiscoveryZambon Spa, Product & Technology Discovery Manager
|
- Astrazeneca R & D Lund, Associate Professor Research Physician
- Imperial College Faculty of Medicine, Chair in Acute Medicine
- Novartis International, Head of Global Advocacy
- Topigen Pharmaceuticals, Chief Executive Officer
- Biotie Therapies, VP Inflammatory Disease Area
- Boehringer Ingelheim, Vice President
- GlaxoSmithKline, Senior Regulatory Scientist
- Boehringer Ingelheim, Senior Research Physician
- Medimmune, Senior Research Scientist
- Napp Pharmaceuticals, Area Sales Manager
- National University Of Singapore, Associate Professor
- Pacific Northwest National Laboratory, Director, Facilities for Systems Biology & Applications
- Synairgen, Managing Director
- UCB Belgium, VP, Clinical Research Immunology
|
- Chiesi Farmaceutici, Head of Corporate Clinical Development
- Imperial College School of Medicine (N.H.L.I.), Professor of Adult Respiratory Medicine
- Novartis Pharmaceuticals, Principal Scientist
- UCB-Celltech, Senior Scientist
- Boehringer Ingelheim, Clinical Monitor, Project Manager
- Genentech, Senior Clinical Scientist Specialist
- Boehringer Ingelheim, Medical Adviser
- Hydra Biosciences, Chief Scientific Officer
- Laboratorios Almirall, Clinical Trial Manager
- Merck Sharp & Dohme, Regulatory Affairs Manager
- Nycomed Belgium, Medical Director
- Pfizer, Daphne Jackson Fellow (Post Doc)
- Sanofi Aventis, Researcher
- Syntaxin, Clinical Research Scientist
- Vectura, Development Director
|
Venue details
Le Méridien Munich
Bayerstrasse 41
Munich, Bavaria 80335
Germany
Phone: (49)(89) 24220
Le Méridien Munich, a chic sanctuary amidst a bustling modern city, reflects Munich’s old world grandeur and offers access to the city’s legendary sites. Medieval palaces dating from the first dukes of Munich and Gothic churches are clustered throughout the city centre. Le Méridien Munich provides convenient access to this most charismatic of cities.
Offering 381 elegantly-appointed guest rooms and suites, Le Méridien Munich has all of the old-world flair one expects from a charming European hotel, combined with modern amenities.
High speed Internet access and sleek conference rooms for business meetings provide an elegant atmosphere for corporate events. The hotel’s spa offers a tranquil place to reinvigorate.
|
Events Home Page
